Item 5. Other Information
Item 5. Other Information.
Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements
O n February 12, 2025 , Deborah Charych , a member of the Company's Board of Directors , adopted a Rule 10b5-1 trading plan. Dr. Charych's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential sale of up to 58,917 shares of the Company’s common stock subject to stock options held by Dr. Charych upon exercise of such stock options until December 31, 2025 .
On March 28, 2025 , Punit Dhillon , the Company’s Chief Executive officer and a member of the Company's Board of Directors , adopted a Rule 10b5-1 trading plan. Mr. Dhillon's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for (i) the potential sale of up to 68,846 shares of the Company’s common stock subject to restricted stock units held by Mr. Dhillon until December 31, 2025 , which amount includes the sale of an indeterminate number of shares of the Company's common stock at market prices sufficient to cover Mr. Dhillon's tax liability upon the vesting of such restricted stock units (ii) the potential sale of up to 25,000 shares of the Company’s common stock subject to restricted stock units held by Mr. Dhillon until December 31, 2026 , which amount includes of the sale of an indeterminate number of shares of the Company's common stock at market prices sufficient to cover Mr. Dhillon's tax liability upon the vesting of such restricted stock units, (iii) the potential sale of up to 20,322 shares of the Company’s common stock held by Mr. Dhillon until December 31, 2025 and (iv) the potential sale of up to 50,000 shares of the Company’s common stock held by Mr. Dhillon until December 31, 2026 .
22
Item 6. Exhibits.
3.1 Amended and Restated Articles of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 22, 2024)
3.2 Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.2 to our Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 2, 2021)
31.1* Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
31.2* Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934
32.1* Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2* Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101 The following materials from the Skye Biosciences, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Balance Sheets (Unaudited), (ii) Condensed Consolidated Statements of Operations (Unaudited), (iii) Condensed Consolidated Statements of Cash Flows (Unaudited), (iv) Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited), and (v) related Notes to the Unaudited Condensed Consolidated Financial Statements.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
________
(*) Filed herewith.
+ Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted exhibits or schedules upon request.
23
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Skye Bioscience, Inc.,
a Nevada corporation
May 8, 2025 By: /s/ Punit Dhillon
Punit Dhillon
Its: Chief Executive Officer, Secretary and Director
(Principal Executive Officer)
May 8, 2025 By: /s/ Kaitlyn Arsenault
Kaitlyn Arsenault
Its: Chief Financial Officer
(Principal Financial and Accounting Officer)
24
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.